PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32174814-9	2020	Conclusion: These data indicate that TBB pretreatment prior to SE slows down disease progression during epileptogenesis involving increased KCa2 function, probably due to a persistently decreased CK2 protein expression.	2-ethylhexyl 2,3,4,5-tetrabromobenzoate	37-40	casein kinase 2 beta	Rattus norvegicus	196-199	
32174814-2	2020	Previously, we observed that in vivo casein kinase 2 (CK2) inhibition with 4,5,6,7-tetrabromotriazole (TBB) had anti-epileptogenic effects in the acute epilepsy slice model.	2-ethylhexyl 2,3,4,5-tetrabromobenzoate	103-106	casein kinase 2 beta	Rattus norvegicus	37-52	
32174814-2	2020	Previously, we observed that in vivo casein kinase 2 (CK2) inhibition with 4,5,6,7-tetrabromotriazole (TBB) had anti-epileptogenic effects in the acute epilepsy slice model.	2-ethylhexyl 2,3,4,5-tetrabromobenzoate	103-106	casein kinase 2 beta	Rattus norvegicus	54-57	
32174814-6	2020	Western blot analyses demonstrated that CA1 tissue from TBB-pretreated epileptic animals contained significantly less CK2 than TBB-pretreated controls.	2-ethylhexyl 2,3,4,5-tetrabromobenzoate	56-59	casein kinase 2 beta	Rattus norvegicus	118-121	
30159756-7	2018	CK2 inhibitors (TBB and Ellagic acid), did not affect protection by S117A-FGF2 but prevented protection by mitogenic FGF2.	2-ethylhexyl 2,3,4,5-tetrabromobenzoate	16-19	casein kinase 2 beta	Rattus norvegicus	0-3	
22499119-7	2012	In fact, TBB, a specific inhibitor of CK2, abolished the effects of NaHS.	2-ethylhexyl 2,3,4,5-tetrabromobenzoate	9-12	casein kinase 2 beta	Rattus norvegicus	38-41	
24596964-4	2014	RESULTS: Chronic oral administration of the CK2 inhibitor 4,5,6,7-tetrabromotriazole (TBB) for 4 days prior to brain dissection caused a significant increase of the sAHP-mediating current in both control and epileptic tissues.	2-ethylhexyl 2,3,4,5-tetrabromobenzoate	86-89	casein kinase 2 beta	Rattus norvegicus	44-47	
24596964-5	2014	In contrast, when TBB was acutely applied during the patch-clamp recording, the sAHP remained unaltered, indicating that chronic CK2 inhibition was required for sAHP augmentation.	2-ethylhexyl 2,3,4,5-tetrabromobenzoate	18-21	casein kinase 2 beta	Rattus norvegicus	129-132	
24596964-7	2014	It is important to note that chronic oral TBB administration abolished REDs induced by 0-Mg2+ solution, suggesting that CK2 inhibition indeed has anticonvulsive and perhaps antiepileptogenic properties.	2-ethylhexyl 2,3,4,5-tetrabromobenzoate	42-45	casein kinase 2 beta	Rattus norvegicus	120-123	
27782092-7	2016	In BV-2 microglia, both the expression of the CK2 target phosphorylated alpha-E-catenin and the binding of casein kinase II (CK2) with alpha-E-catenin were elevated by Ac2-26, these effects were counteracted by the CK2 inhibitor TBB and small interfering (si) RNA directed against transcripts of CK2 and FPRs.	2-ethylhexyl 2,3,4,5-tetrabromobenzoate	229-232	casein kinase 2 beta	Rattus norvegicus	125-128	
27782092-7	2016	In BV-2 microglia, both the expression of the CK2 target phosphorylated alpha-E-catenin and the binding of casein kinase II (CK2) with alpha-E-catenin were elevated by Ac2-26, these effects were counteracted by the CK2 inhibitor TBB and small interfering (si) RNA directed against transcripts of CK2 and FPRs.	2-ethylhexyl 2,3,4,5-tetrabromobenzoate	229-232	casein kinase 2 beta	Rattus norvegicus	125-128	
27782092-7	2016	In BV-2 microglia, both the expression of the CK2 target phosphorylated alpha-E-catenin and the binding of casein kinase II (CK2) with alpha-E-catenin were elevated by Ac2-26, these effects were counteracted by the CK2 inhibitor TBB and small interfering (si) RNA directed against transcripts of CK2 and FPRs.	2-ethylhexyl 2,3,4,5-tetrabromobenzoate	229-232	casein kinase 2 beta	Rattus norvegicus	125-128	
27782092-8	2016	Moreover, both TBB and siRNA-mediated inhibition of CK2 blocked Ac2-26-mediated BV-2 microglia migration.	2-ethylhexyl 2,3,4,5-tetrabromobenzoate	15-18	casein kinase 2 beta	Rattus norvegicus	52-55	
19460754-7	2009	CK2 is the likely in vivo CAPS protein kinase based on inhibition of phosphorylation by tetrabromo-2-benzotriazole in PC12 cells and by the identity of in vivo and in vitro phosphorylation sites.	2-ethylhexyl 2,3,4,5-tetrabromobenzoate	88-114	casein kinase 2 beta	Rattus norvegicus	0-3